drugset / Trial / NCT00699166
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.
Timeline
- Start
- 2004-04
- Primary completion
- 2005-09
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DNK333 | Small molecule | 25 mg | Oral |
| Subject | DNK333 | Small molecule | 100 mg | Oral |